479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819099937294516224 |
|---|---|
| author | Andrea Bullock Justin Moser Daruka Mahadevan Michael Gordon Przemyslaw Twardowski Apostolia Tsimberidou Breelyn Wilky Waldo Ortuzar Feliu Anthony El-Khoueiry Steven O’Day Bruno Bockorny Katherine Rosenthal |
| author_facet | Andrea Bullock Justin Moser Daruka Mahadevan Michael Gordon Przemyslaw Twardowski Apostolia Tsimberidou Breelyn Wilky Waldo Ortuzar Feliu Anthony El-Khoueiry Steven O’Day Bruno Bockorny Katherine Rosenthal |
| author_sort | Andrea Bullock |
| collection | DOAJ |
| first_indexed | 2024-12-22T00:54:49Z |
| format | Article |
| id | doaj.art-e5ddc153157d45b0bd1cab923730850e |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T00:54:49Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-e5ddc153157d45b0bd1cab923730850e2022-12-21T18:44:21ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.479479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I resultsAndrea Bullock0Justin Moser1Daruka Mahadevan2Michael Gordon3Przemyslaw Twardowski4Apostolia Tsimberidou5Breelyn Wilky6Waldo Ortuzar Feliu7Anthony El-Khoueiry8Steven O’Day9Bruno Bockorny10Katherine Rosenthal118Beth Israel Deaconess Hospital, boston, MA, USAOncology, Huntsman Cancer Institute, Salt Lake City, Utah, USAAff1 0000 0001 2168 186Xgrid.134563.6Department of Medicine Division of Hematology/OncologyUniversity of Arizona Cancer Center 1515. N. Campbell Avenue, Room 1905 85724 Tucson AZ USA4HonorHealth Cancer Care Network, Scottsdale, AZ, USAAff5 grid.410425.60000000404218357City of Hope Duarte CA USA1The University of Texas MD Anderson Cancer Center, Houston, TX, USA3University of Colorado Anschutz Medical, Aurora, CO, USA4Agenus inc, Lexington, Massachusetts, USA1University of Southern California, Los Angeles, CA, USA4John Wayne Cancer Institute, Santa Monica, CA, USA2Beth Israel Deaconess Medical Center, Boston, MA, USA8Agenus Inc, Lexington, USA |
| spellingShingle | Andrea Bullock Justin Moser Daruka Mahadevan Michael Gordon Przemyslaw Twardowski Apostolia Tsimberidou Breelyn Wilky Waldo Ortuzar Feliu Anthony El-Khoueiry Steven O’Day Bruno Bockorny Katherine Rosenthal 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results Journal for ImmunoTherapy of Cancer |
| title | 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results |
| title_full | 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results |
| title_fullStr | 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results |
| title_full_unstemmed | 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results |
| title_short | 479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results |
| title_sort | 479 agen1181 an fc enhanced anti ctla 4 antibody alone and in combination with balstilimab anti pd 1 in patients with advanced solid tumors initial phase i results |
| work_keys_str_mv | AT andreabullock 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT justinmoser 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT darukamahadevan 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT michaelgordon 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT przemyslawtwardowski 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT apostoliatsimberidou 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT breelynwilky 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT waldoortuzarfeliu 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT anthonyelkhoueiry 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT stevenoday 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT brunobockorny 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults AT katherinerosenthal 479agen1181anfcenhancedantictla4antibodyaloneandincombinationwithbalstilimabantipd1inpatientswithadvancedsolidtumorsinitialphaseiresults |